DataMeds Regains Compliance With NASDAQ Listing Standards
Stockholders’ equity exceeded the required $2.5 million, but compliance must be demonstrated in the next periodic report.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DataMeds AI (NASDAQ:MEDS) has regained compliance with Nasdaq’s minimum stockholders’ equity requirement, following a notification dated October 19, 2026. The requirement is $2.5 million, and the company’s October 13 filing confirmed equity exceeded that threshold. An October 16 filing supplied additional details on the events behind the increase.
Nasdaq had notified DataMeds of delisting proceedings in April over bid-price and equity deficiencies. Bid-price compliance was restored in June. The company may face delisting if it fails to demonstrate compliance when filing its next periodic report.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointStockholders’ equity exceeded $2.5 million, restoring compliance with Nasdaq’s Equity Rule.
- Minor pointBid-price compliance was restored on June 9, 2026, resolving the earlier $1.00 minimum-price deficiency.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Delisting remains possible if DataMeds fails to demonstrate compliance upon filing its next periodic report.
Details
Market Reaction – MEDS
On Oct 20, the day this news came out, the latest delayed price for MEDS is 1.50% below the previous close. Argus tracked a peak move of +4.0% during the session. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $2.63. Relative volume is above average at 1.7x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Minimum stockholders' equity
- $2.5 million
- Nasdaq Equity Rule threshold for compliance
Key Terms
form 8-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, FL / ACCESS Newswire / October 20, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence (artificial intelligence) platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated October 19, 2026, informing DataMEDS that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). In order to regain compliance with the Equity Rule, DataMEDS needed to have a minimum stockholders' equity of
The Company originally received a notice of delisting from NASDAQ on April 13, 2026 outlining the basis for delisting proceedings:
1) | Failure to meet minimum | ||
2) | Failure to maintain a minimum of |
NASDAQ notified the Company on June 9, 2026 that it had regained bid-price compliance and provided the Company additional time to attempt to regain compliance with the minimum stockholders' equity requirement.
Based on a Company Form 8-K filing on October 13, 2026 that confirmed the Company's stockholder's equity exceeded
For more information, visit www.datamedsai.com or contact James Lambert, Vice President at Rubenstein Public Relations, at jlambert@rubensteinpr.com or at 212-805-3024.
About DataMeds AI, Inc. (DBA DataMeds SI)
DataMeds SI (NASDAQ:MEDS) is a healthcare company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its Health IT platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates the super intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Pharmacy provides pharmacy dispensing and related services, including the distribution of products developed by Tollo Health. DataMEDS has licensed patented GLP-1 patient management technology from REBOOT, a subsidiary of Data Health Partners. The Company's Helomics Corporation subsidiary operates a CLIA-certified laboratory in Pittsburgh offering the ChemoFx® Assay.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, the Company's anticipated business strategy, operating plans and growth opportunities; the Company's ability to maintain compliance with Nasdaq listing standards; the Company's liquidity, capital resources and ability to fund operations; the Company's ability to maintain compliance with Nasdaq listing standards, the development of a proprietary blockchain and the development of provider-network features, the creation of the Health Lives Here pharmacy network, the success of the NFL Alumni Health partnership, the companies' proposed transaction with DataVault AI Inc. (NASDAQ:DVLT), Scilex Holding Company, EOS Holdings and HealthBridge Advisors (controlling shareholder of Tollo Health, LLC); the satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment approaches; the companies' ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the companies' technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
DataMeds AI Media Contact
James Lambert, Vice President
Rubenstein Public Relations
Phone: 212.805.3024
Email: jlambert@rubensteinpr.com
DataMeds AI Investor Contact
Investor Relations: IR@datamedsai.com
###
SOURCE: DataMEDS AI, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Has DataMeds AI (MEDS) regained Nasdaq listing compliance?
DataMeds AI received confirmation dated October 19, 2026 that it had regained compliance with Nasdaq’s minimum stockholders’ equity requirement. Its October 13 filing confirmed equity exceeded the required $2.5 million. Nasdaq had previously confirmed bid-price compliance on June 9, 2026.
Could DataMeds AI (MEDS) still face delisting?
DataMeds AI may be subject to delisting if it fails to demonstrate compliance upon filing its next periodic report. The restored equity compliance does not remove that stated requirement.